H.C. Wainwright lowered the firm’s price target on Lexaria Bioscience (LEXX) to $5 from $7 and keeps a Buy rating on the shares. In April, the company closed a registered direct offering for 2M common shares at $1 per share for gross proceeds of $2M, notes the analyst, who believes that the company will need to raise additional capital within the next 12 months to fund operations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience Achieves 50 Patents Milestone with New International Grants
- Lexaria Bioscience receives two international patents
- Lexaria’s Oral Liraglutide Shows Promise in Reducing Adverse Events
- Lexaria Bioscience announces completion of GLP-1-H25-5 study
- Lexaria Bioscience to Engage with Industry Leaders at BIO International Convention